AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
All Articles
Zuma 7 trial shows statistically significant overall survival benefit for yescarta
By Editorial Team
By Dr. Luke Fletcher [Willamette Valley Cancer Institute & Research Center](https://www.oregoncancer.com/) _The Zuma 7 trial is a randomized, open-label multicenter study for patients with primary ref...
Zuma 7 trial shows statistically significant overall survival benefit for yescarta
By Editorial Team
By Dr. Luke Fletcher [Willamette Valley Cancer Institute & Research Center](https://www.oregoncancer.com/) _The Zuma 7 trial is a randomized, open-label multicenter study for patients with primary ref...
Zuma 7 trial shows statistically significant overall survival benefit for yescarta
By Editorial Team
By Dr. Luke Fletcher [Willamette Valley Cancer Institute & Research Center](https://www.oregoncancer.com/) _The Zuma 7 trial is a randomized, open-label multicenter study for patients with primary ref...
2022 Updates in Lung Cancer Treatment
By Editorial Team
2022 Updates in Lung Cancer Treatment
By Editorial Team
2022 Updates in Lung Cancer Treatment
By Editorial Team
2023 Summit on Cancer Health Disparities (SCHD)
By Editorial Team
2023 Summit on Cancer Health Disparities (SCHD)
By Editorial Team
2023 Summit on Cancer Health Disparities (SCHD)
By Editorial Team
AGILE trial—Ivosidenib plus Azacitidine versus Azacitidine in IDH1 Mutated Acute Myeloid Leukemia
By Editorial Team
Dr. Aditi Sharma of [Barbara Ann Karmanos Cancer Institute](https://www.karmanos.org/karmanos/karmanos-home) & Dr. Abhishek Mangaonkar of [Mayo Clinic](https://www.mayoclinic.org/) In the phase III ...
AGILE trial—Ivosidenib plus Azacitidine versus Azacitidine in IDH1 Mutated Acute Myeloid Leukemia
By Editorial Team
Dr. Aditi Sharma of [Barbara Ann Karmanos Cancer Institute](https://www.karmanos.org/karmanos/karmanos-home) & Dr. Abhishek Mangaonkar of [Mayo Clinic](https://www.mayoclinic.org/) In the phase III ...
AGILE trial—Ivosidenib plus Azacitidine versus Azacitidine in IDH1 Mutated Acute Myeloid Leukemia
By Editorial Team
Dr. Aditi Sharma of [Barbara Ann Karmanos Cancer Institute](https://www.karmanos.org/karmanos/karmanos-home) & Dr. Abhishek Mangaonkar of [Mayo Clinic](https://www.mayoclinic.org/) In the phase III ...
Announcing Binaytara Summit on Cancer Health Disparities 2023
By Editorial Team
The conference will be held at the Grand Hyatt in Seattle on April 28-30, 2023 ------------------------------------------------------------------------------ We invite you to attend the 2023 Summit o...
Announcing Binaytara Summit on Cancer Health Disparities 2023
By Editorial Team
The conference will be held at the Grand Hyatt in Seattle on April 28-30, 2023 ------------------------------------------------------------------------------ We invite you to attend the 2023 Summit o...
Announcing Binaytara Summit on Cancer Health Disparities 2023
By Editorial Team
The conference will be held at the Grand Hyatt in Seattle on April 28-30, 2023 ------------------------------------------------------------------------------ We invite you to attend the 2023 Summit o...
Volunteer Spotlight: June Zhu
By The Cancer News Team
Zhu Shares About Her Experience Volunteering at Binaytara
Volunteer Spotlight: June Zhu
By The Cancer News Team
Zhu Shares About Her Experience Volunteering at Binaytara
Volunteer Spotlight: June Zhu
By The Cancer News Team
Zhu Shares About Her Experience Volunteering at Binaytara
A recap from our 2nd Annual Charity Gala Dinner
By Editorial Team
Binaytara’s Second Annual Gala Dinner was held on July 24, 2021, at the Crowne-Plaza Downtown Seattle and over 100 guests came out to support the organization’s efforts to eliminate global cancer care...
A recap from our 2nd Annual Charity Gala Dinner
By Editorial Team
Binaytara’s Second Annual Gala Dinner was held on July 24, 2021, at the Crowne-Plaza Downtown Seattle and over 100 guests came out to support the organization’s efforts to eliminate global cancer care...
A recap from our 2nd Annual Charity Gala Dinner
By Editorial Team
Binaytara’s Second Annual Gala Dinner was held on July 24, 2021, at the Crowne-Plaza Downtown Seattle and over 100 guests came out to support the organization’s efforts to eliminate global cancer care...
What's going on with brain cancer?
By Editorial Team
Although brain cancer is one of the [rarest](https://www.cancer.net/cancer-types/brain-tumor/statistics) cancers, with a likelihood that it will develop during one’s lifetime being 1%, it is also one ...
What's going on with brain cancer?
By Editorial Team
Although brain cancer is one of the [rarest](https://www.cancer.net/cancer-types/brain-tumor/statistics) cancers, with a likelihood that it will develop during one’s lifetime being 1%, it is also one ...
What's going on with brain cancer?
By Editorial Team
Although brain cancer is one of the [rarest](https://www.cancer.net/cancer-types/brain-tumor/statistics) cancers, with a likelihood that it will develop during one’s lifetime being 1%, it is also one ...
Welcoming Dr. Aparna Parikh to our board of directors
By Editorial Team
[Dr. Aparna Parikh](https://www.massgeneral.org/cancer-center/doctors/19980/Aparna-Parikh), an assistant professor of medicine at Harvard University and medical-oncologist at Massachusetts General Hos...
Welcoming Dr. Aparna Parikh to our board of directors
By Editorial Team
[Dr. Aparna Parikh](https://www.massgeneral.org/cancer-center/doctors/19980/Aparna-Parikh), an assistant professor of medicine at Harvard University and medical-oncologist at Massachusetts General Hos...
Welcoming Dr. Aparna Parikh to our board of directors
By Editorial Team
[Dr. Aparna Parikh](https://www.massgeneral.org/cancer-center/doctors/19980/Aparna-Parikh), an assistant professor of medicine at Harvard University and medical-oncologist at Massachusetts General Hos...
New Targets in Squamous NSCLC: Old Mechanisms, Novel Approaches, and Two Phase 3 Trials Worth Watching
By Editorial Team
The transformation of lung adenocarcinoma treatment through molecular targeting is one of oncology’s great recent successes.
New Targets in Squamous NSCLC: Old Mechanisms, Novel Approaches, and Two Phase 3 Trials Worth Watching
By Editorial Team
The transformation of lung adenocarcinoma treatment through molecular targeting is one of oncology’s great recent successes.
New Targets in Squamous NSCLC: Old Mechanisms, Novel Approaches, and Two Phase 3 Trials Worth Watching
By Editorial Team
The transformation of lung adenocarcinoma treatment through molecular targeting is one of oncology’s great recent successes.